Skip to content

Dimensional Changes of Peri-implant Tissues Following Jumping Gap Grafting Using Erythropoietin Gel Mixed With Xenograft.

Dimensional Changes of Peri-implant Tissues Following Jumping Gap Grafting Using Erythropoietin Gel Mixed With Xenograft. (A Randomized Controlled Clinical Study)

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07523412
Enrollment
26
Registered
2026-04-13
Start date
2026-04-12
Completion date
2026-11-12
Last updated
2026-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peri-implant Bone and Soft Tissues

Keywords

Radiographic assessment of alveolar bone width (0-6 months)., Radiographic assessment of alveolar bone height (0-6 months)., Clinical assessment (Soft tissue height and thickness): (0-3-6 months).

Brief summary

This study will be conducted to compare the effect of Erythropoietin gel mixed with xenograft versus xenograft alone in grafting the jumping gap around immediate implant.

Detailed description

The distance between the implant and the defect's surrounding wall is known as the horizontal bone defect (also known as the "Jumping Distance" or "Gap"). By filling the space between the implant and the buccal bone walls of recently extracted sockets, bone grafting material promotes hard tissue repair and reduces marginal bone loss. To increase bone contact to the implant surface and lessen gingival recession brought on by horizontal bone resorption, bone grafting at the gap is advised. Various methods have been employed to bridge the gap in bone: autograft and allograft-based bone substitutes, which can be utilized separately or in conjunction with other materials like freeze-dried bone, xenograft (like bovine bone), and ceramic-based bone graft alternatives like calcium phosphate, calcium sulphate, and bio-glass. According to a study by Bianchi S, using xenografts improved the osteoconductive qualities of bone regeneration by demonstrating significant cellular activity. The potential of EPO to enhance bone growth and tissue protection by reducing ischemia and inflammatory responses is one of its non-hematopoietic properties. EPO stimulates the development of mesenchymal stem cells (MSCs) into osteoblasts and participates in the interactions of osteoblasts and osteoclasts to promote bone formation.

Interventions

DRUGErythropoetin gel mixed with xenogenic bone graft

Patients with EPO gel mixed with xenogenic bone graft in the jumping gap of immediate implant.

OTHERXenogenic bone with gelling aget CMC ( carboxymethyl cellulose)

Patients with xenogenic bone graft and gelling agent in the jumping gap of immediate implant.

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

1. Both genders aged from 20 to 50 years. 2. Systemically free patients as evidenced by Burket's oral health history questionnaire. 3. Patients need the extraction of non-restorable maxillary tooth in esthetic zone and the possibility of immediate placement of implants on the same site with Intact labial plate and interproximal bone levels (socket type 1). 4. Gap space of more than 2 mm between the implant and buccal bone.

Exclusion criteria

1. Smokers. 2. Pregnant or lactating females. 3. Acute infection at the implant site 4. Patients under any medication that affects the healing. 5. Vulnerable group of patients (prisoners, handicapped, and decisional impaired individuals).

Design outcomes

Primary

MeasureTime frameDescription
Radiographic assessment0-6 monthsRadiographic assessment of alveolar bone width by CBCT

Secondary

MeasureTime frameDescription
Radiographic assessment0-6 monthsRadiographic assessment of alveolar bone height by CBCT
Clinical assessment0-3-6 monthsClinical assessment (Soft tissue height and thickness)

Countries

Egypt

Contacts

CONTACTAhmed S Ahmed
AhmedShakerTaha@dent.asu.edu.eg+20 1211380626

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 16, 2026